Literature DB >> 22138006

Impact of prosthesis-patient mismatch on the regression of secondary mitral regurgitation after isolated aortic valve replacement with a bioprosthetic valve in patients with severe aortic stenosis.

Emiliano Angeloni1, Giovanni Melina, Philippe Pibarot, Umberto Benedetto, Simone Refice, Giuseppino M Ciavarella, Antonino Roscitano, Riccardo Sinatra, John R Pepper.   

Abstract

BACKGROUND: Secondary mitral regurgitation (SMR) is generally reduced after isolated aortic valve replacement (AVR), but there is important interindividual variability in the magnitude of this reduction. Prosthesis-patient mismatch (PPM) may hinder normalization of left ventricular geometry and pressure overload following AVR, therefore we aimed to investigate the relationship between PPM and regression of SMR following AVR for aortic valve stenosis. METHODS AND
RESULTS: A total of 419 patients with AS who underwent isolated AVR at 2 institutions and presenting moderate SMR (mitral regurgitant volume 30 to 45 mL/beat) not considered for surgical correction were included in this study. Clinical and echocardiographic follow-up were completed at a median follow-up time of 37 months. PPM was defined as an indexed effective orifice area ≤0.85 cm(2)/m(2) and was found in 170/419 patients (40.6%). There were no significant differences in baseline and operative characteristics between patients with or without PPM. Patients with PPM had less regression of SMR following AVR compared with those with no PPM (change in mitral regurgitant volume: -11±4 versus -17±5 mL, respectively; P<0.0001). Variables significantly associated with postoperative change in mitral regurgitant volume on univariable analysis were entered in a multivariable linear regression model, which showed indexed effective orifice area (P<0.0001) and left atrial diameter (P=0.006) to be independently associated with mitral regurgitant volume improvement. Patients with PPM also had less postoperative improvement in 6-minute walking test distance (80±78 versus 42±41 m, P<0.0001).
CONCLUSIONS: PPM is associated with lesser regression of SMR following AVR. This unfavorable effect was associated with worse functional capacity. These findings emphasize the importance of operative strategies aiming to prevent PPM in patients with aortic valve stenosis and concomitant SMR.

Entities:  

Mesh:

Year:  2011        PMID: 22138006     DOI: 10.1161/CIRCIMAGING.111.967612

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  6 in total

Review 1.  Prosthesis-Patient Mismatch After Aortic Valve Replacement.

Authors:  Abdellaziz Dahou; Haïfa Mahjoub; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

2.  Impact of Mitral Regurgitation on Clinical Outcomes After Transcatheter Aortic Valve Implantation.

Authors:  Crochan J O'Sullivan; David Tüller; Rainer Zbinden; Franz R Eberli
Journal:  Interv Cardiol       Date:  2016-05

Review 3.  Prosthesis-patient mismatch in aortic stenosis.

Authors:  Kentaro Honda; Yoshitaka Okamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-10-17

4.  Prosthesis-Patient Mismatch after Mitral Valve Replacement: Comparison of Different Methods of Effective Orifice Area Calculation.

Authors:  In Jeong Cho; Geu Ru Hong; Seung Hyun Lee; Sak Lee; Byung Chul Chang; Chi Young Shim; Hyuk Jae Chang; Jong Won Ha; Namsik Chung
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

5.  Impact of prosthesis-patient mismatch after mitral valve replacement in rheumatic population: Does mitral position prosthesis-patient mismatch really exist?

Authors:  Seung Hyun Lee; Byung Chul Chang; Young-Nam Youn; Hyun Chel Joo; Kyung-Jong Yoo; Sak Lee
Journal:  J Cardiothorac Surg       Date:  2017-10-10       Impact factor: 1.637

6.  Prosthesis-patient mismatch after mitral valve replacement: a single-centered retrospective analysis in East China.

Authors:  Armah M Akuffu; Haige Zhao; Junnan Zheng; Yiming Ni
Journal:  J Cardiothorac Surg       Date:  2018-10-03       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.